Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Diversified Specialty and Generics Portfolio

We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

Driven by Innovation

The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year.

Our core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development.

Our capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled release dosage forms.

Our R&D is led by a strong team of more than 2000 scientists.

Global Footprint

From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India.

In the US, we are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.

We are the largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.

We are present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.

Our presence in emerging markets and the developing world enables our teams to cross-sell and build brands with ease.